Drugmakers turn to artificial intelligence (AI); new reports of vaccine appointment cancellations or insurance issues; Biden plans to clear Americans’ credit scores of medical debt.
Major pharmaceutical companies, including Amgen, Bayer, and Novartis, are increasingly deploying artificial intelligence (AI) to revolutionize clinical trials, according to Reuters. AI tools, like Amgen's ATOMIC, are streamlining patient recruitment by identifying high-performing clinics and doctors, significantly reducing enrollment times. Moreover, AI is aiding in the design of trials, potentially eliminating the need for placebo groups through the creation of external control arms based on real-world patient data. This AI-driven approach not only expedites drug development but also offers substantial cost savings.
The rollout of the newest COVID-19 vaccines, authorized for individuals 6 months and older, is facing challenges, according to the Associated Press. Some individuals have had to cancel appointments due to insurance companies not yet updating billing codes for the vaccines, while others have seen appointments canceled because of supply issues. Slow shipments and order backlogs have contributed to limited vaccine availability in certain areas. Although Moderna and Pfizer say they have adequate supply, logistical hiccups are affecting the distribution process, causing frustration for those eagerly seeking vaccinations.
The Biden administration has revealed its intentions to develop federal rules that would prevent unpaid medical bills from affecting patients' credit scores, according to Kaiser Health News. This action comes in response to the significant problem of medical debt affecting about 100 million Americans, leading many to take on additional work, lose their homes, and even ration essentials. These new regulations, although expected to face opposition from the medical industry, have garnered robust support from patient and consumer groups who have long advocated for stronger protections against medical debt. While the process to enact these rules may be lengthy, they offer potential relief to those facing the devastating consequences of medical debt on their credit reports and financial lives.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More